Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial - Nitti, V W; Chapple, C R; Walters, C (Int J Clin Pract, 2014)
et al.